Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous tests revealed that many Ranitidine samples contained unsafe levels of NDMA impurities. The ICMR has been asked to conduct a study to assess the drug's...
BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts
BDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million investment. Chairman Dharmesh Shah mentioned the company is evaluating potential units and expects a decision within months, funded by internal accruals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cK9xTlR
via...
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India through share swap
Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug
Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million,...
Max Healthcare lines up Rs 6,000 crore for expansion
Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pnvJMtA
via I...
Max Healthcare Institute to invest Rs 6,000 cr to add 3,700 beds by 2028
Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic...
Medanta to invest Rs 500 cr to set up 400-bed hospital in Guwahati
Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million...
Dr Reddy's to introduce Sanofi's novel drug in India
Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing lower respiratory tract disease in newborns caused by RSV. Dr. Reddy's will exclusively promote and distribute Beyfortus in India, with a launch expected in the second quarter of the current fiscal year, following regulatory...
Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itself
A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SMA), potentially earning 115 times its clinical trial expenses. Knowledge Ecology International estimates trial costs at $50 million, while Roche's risdiplam revenue reached $5.8 billion. Roche defends its pricing,...
Get evergreening patent requests very often, these benefit select few cos: Piyush Goyal
Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as 'evergreening,' for prioritizing corporate profits over global healthcare access. Goyal highlighted Ayushman Bharat scheme, providing free healthcare to over 620 million people. He emphasized India's...
Zydus gets 6 observations from USFDA for API unit
Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug...
SS Innovations International to list on US exchange Nasdaq
SS Innovations International, an Indian surgical robotics company, is set to list on the Nasdaq under the ticker 'SSII' on April 25. The company experienced substantial revenue growth, reaching $20.6 million in 2024, a 3.5-fold increase from the previous year.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MAwe3r7
via IFT...
Reckitt Benckiser's rare reflection: India a big growth driver
Reckitt Benckiser's CEO, Kris Licht, highlights India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals, through initiatives like 'Dettol...
To speed up delivery, govt exempts orphan drugs from testing at ports
To ensure timely access to life-saving orphan drugs for patients, the government has exempted mandatory sampling and testing at port offices. The drug regulator will now release consignments based on a legal undertaking from the importer. This decision addresses challenges like small volumes and specialized testing needs, streamlining the process and...
Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively
The Delhi High Court has provided relief to pharma companies like Glenmark Pharmaceuticals and Zuventus Healthcare, ruling that the ban on fixed-dose combinations for children under four will be applied prospectively. The court directed companies to issue advisories to doctors and publish notices in national newspapers, informing that the drugs should...
Delhi HC orders cough syrup makers to warn against use in children below 4, issue public notices
Glenmark and Zuventus Healthcare have approached the Delhi High Court against the Centre’s April 15 notification banning the use of certain cough syrups for children below four years of age. The companies argued that the order should not apply retrospectively.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7BHbMS1
via IFT...
Drugs panel considering proposal to rein in sale of OTC medicines to prevent misuse
India's drug advisory board is considering restricting over-the-counter medication sales to prevent misuse and ensure patient safety. The proposal limits OTC sales to 27 drugs, including antipyretics and painkillers, with dosage and quantity restrictions. The board aims to increase accessibility while ensuring patient safety by excluding several currently...
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, used for treating specific bone marrow and blood cancers. The approved tablets, available in multiple strengths, are therapeutically equivalent to Bristol-Myers Squibb's Sprycel. Launch is anticipated in Q1FY26, targeting...
Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton Bharat
India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a 326% surge in values for Q1 2025. Despite a slight quarterly dip due to macroeconomic factors, high-value deals are on the rise, particularly in M&A and PE activity, signaling confidence in scalable models and...
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply...
Dr Reddy's, Lupin recall products in US due to labelling, manufacturing errors: USFDA
Dr. Reddy's Laboratories and Lupin are recalling products in the US due to labeling and manufacturing issues. Dr. Reddy's is recalling an antiepileptic drug due to a labeling mix-up, where infusion bags were incorrectly labeled. Lupin Pharmaceuticals is recalling an antidepressant medication due to failed impurity specifications. The USFDA has classified...
India faces a silent cervical cancer crisis: Every 8 minutes, a woman dies, but HPV vaccine and early screening could prevent it
The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve prevention and treatment in India. The organisation emphasised the importance of indigenous HPV tests and vaccines in cancer screening, alongside strengthening diagnostic infrastructure. Key recommendations include early detection,...
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become...
Russia-Ukraine war: Indian pharma firm caught in crossfire, lobby seeks PM Modi’s help
An Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly struck by a missile, prompting the Federation of Pharma Entrepreneurs to seek Prime Minister Modi's intervention.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKe1D3p
via IFT...
Shivinder Mohan Singh moves NCLT, files plea for personal insolvency
Shivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding assets. Facing a Rs 3,500 crore recovery to Daiichi Sankyo, Singh's assets are largely attached or devalued due to litigation and mismanagement within RHC Holding.
from Healthcare/Biotech-Industry-Economic Times...
Pharmacists seek clarity on banned cough syrup stock
Pharmacists are seeking clarification from the DCGI regarding the handling of recently banned cough syrups for children under four, specifically concerning existing stocks and prescriptions. The IPA has requested guidance on whether to return stocks or sell them until depleted, and if prescriptions for young children can be dispensed. The industry...
Centre pushes for 'one nation, one swap transplant' system to boost kidney donations
India is set to promote kidney swap transplants nationwide, aiming to increase transplant numbers by up to 15%. Following a directive from NOTTO, states and union territories are encouraged to implement swap transplants, a practice already recognized but underutilized. The initiative includes a standardized document list and the potential creation...
Yoga vs Strengthening exercises: Which is better for knee osteoarthritis? Study reveals surprising results
A recent study indicates yoga is as effective as strengthening exercises for managing knee osteoarthritis, offering improvements in pain, quality of life, and depression. Experts highlight yoga's comprehensive approach, addressing mental health, balance, and joint mobility. Both yoga and resistance training achieve similar physiological goals through...
US tariff chaos, global headwinds hit pharma GCC hiring in India
Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharmaceutical and healthcare GCCs. Experts predict a 6-7% reduction in net talent addition this fiscal year as companies adopt a cautious approach. Despite this temporary slowdown, India remains a vital hub for R&D, with long-term growth prospects fueled...
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially...
Health ministry in talks to shield India’s pharma industry amid impending tariffs from team Trump
India's health ministry is actively exploring strategies to protect its pharmaceutical industry from potential US tariffs. Discussions involve a fixed tariff regime and waiving import tariffs on US pharma products. The US is also raising concerns about nutraceutical imports, prompting India to consider regulatory changes, potentially impacting the...
Divi's Lab inks supply pact with global pharmaceutical entity
Divi's Laboratories announced a long-term supply agreement with a global pharmaceutical company, focusing on manufacturing and supplying advanced intermediates. The company anticipates significant revenue generation from this partnership.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KBMRzNm
via IFT...
Govt bans select cough syrups for kids below 4 years
The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four due to safety concerns. Drug regulators are mandating manufacturers to include explicit warnings on labels and packaging. This decision follows recommendations from India's apex drug body after examining the fixed-dose...
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has received the United States Food and Drug Administration approval. The approval allows them to market Carbamazepine tablets in the US. This medication is a generic version of Tegretol Tablets. Carbamazepine tablets are anticonvulsants. They also treat pain from trigeminal neuralgia. The market size for these tablets is estimated...
Assam govt plans to transform GMCH into one of India's largest hospitals
Assam Chief Minister Himanta Biswa Sarma is undertaking steps to transform Gauhati Medical College and Hospital into one of India's largest. The upcoming Mother and Child Care Hospital on GMCH premises will offer specialized pediatric care with 800 beds.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYoetgL
via IFT...
Trump’s executive order on drug pricing could be a booster for Indian pharma industry
Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtGwUZb
via IFT...
In major development in pharma, halt order enforced on production and sale of 35 fixed-dose combination drugs
India's drug regulator, CDSCO, has ordered a halt to the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs due to safety concerns. These drugs, including pain relievers and diabetes medications, lacked proper evaluation before approval. The CDSCO has directed state and Union territory regulators to reassess approval procedures,...
Mercury soars, and so do sales of rehydration drinks in India
India is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in March, leading the oral electrolyte market's growth. Doctors are reporting an increase in digestive disorder cases, further fueling the need for rehydration solutions as temperatures rise and waterborne diseases become...
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.
from...
Biocon Biologics secures market entry for Yesafili in US
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon Biologics to launch Yesafili in the US by the second half of 2026, or earlier under certain conditions. Yesafili, already approved by the USFDA, is intended...
Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 crore from Indian pharma giants
Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing...
Pharma companies may feel heat of US tariffs on China
India's pharmaceutical industry is bracing for potential disruptions due to US tariffs on Chinese goods. Experts warn that China may increase prices for key pharmaceutical ingredients exported to India to offset tariff costs. With India heavily reliant on China for APIs and intermediates, this could lead to higher medicine production costs.
from Healthcare/Biotech-Industry-Economic...
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claim
Dr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the company aimed to cut manpower expenses by 25%, prompting high-salaried employees, including those earning over ₹1 crore annually, to resign. Voluntary retirement was also reportedly offered to R&D employees aged...
Dr Reddy’s slashing jobs to cut costs by 25%; asks several Rs 1 crore+ earners to resign
Dr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, including those earning over ₹1 crore annually, are being asked to resign. The R&D division is offering voluntary retirement to employees aged 50–55. Some divisions, like digital therapeutics, may face shutdowns or...
India's healthcare expenditure expected to surge from 3.3% to 5% of its GDP by 2030: CareEdge
India’s healthcare spending is projected to rise from 3.3% to 5% of GDP by 2030, according to a CareEdge report. The sector is poised for major transformation driven by investments, government initiatives, and demographic shifts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ShcUkJe
via IFT...
Glenmark, Sun Pharma, Zydus recall products in US
Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the USFDA. Glenmark is recalling over 25 products, while Sun Pharma is recalling Gabapentin capsules due to cross-contamination. Zydus is recalling chlorproMAZINE Hydrochloride Tablets due to an impurity exceeding the...
Healthcare investors go for full-body check-up: Forensic due diligence rise as sector faces scrutiny
Investors are increasingly scrutinizing India's healthcare sector, including pharma companies and hospitals, due to concerns about potential malpractices and regulatory scrutiny. They are conducting in-depth due diligence, examining doctor-management relationships, referral practices, and the appropriateness of treatments. This heightened scrutiny...
Any tariffs on pharma sector would be counterproductive for Americans: Wockhardt Chairman Habib Khorakiwala
Wockhardt Chairman Habib Khorakiwala warns that potential US tariffs on pharmaceutical products would harm Americans. He highlights India's crucial role in supplying 40% of US prescription drugs at reasonable prices. Imposing tariffs would increase healthcare costs for Americans, given the lengthy FDA approval process and higher manufacturing and research...
Weight is over! Pharma companies race to make weight-loss drug semaglutide
Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic versions of Novo Nordisk's Wegovy and Ozempic as patents expire. These companies are developing novel technologies and aligning capacities for delivery pens, targeting both the Indian market and exports.
from Healthcare/Biotech-Industry-Economic...
USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm
Aurobindo Pharma Ltd announced that the USFDA issued a Form 483 with 11 observations following an inspection of its Aurolife Pharma LLC's Raleigh plant in North Carolina. The company stated that the observations are procedural and it will respond with corrective actions. Aurobindo Pharma anticipates no significant impact on its operations or supplies...
Morepen to hire 1,000 medical representatives to strengthen formulations biz
Morepen Laboratories plans to significantly expand its medical representative team, adding over 1,000 members in the next three years, with 200 joining in FY26. This strategic move aims to bolster its formulations business and capture a larger share of the growing Indian pharmaceutical market, targeting Rs 1,000 crore in five years.
from Healthcare/Biotech-Industry-Economic...
Cipla gets USFDA nod for generic cancer drug
Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100 mg/vial). This medication is indicated for treating metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hv3QJnr
via...
Tariff risks cloud near-term pharma deals outlook: Rothschild's Stefano Beschi
Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u4w5GE3
via...
US court lifts restrictions on Sun Pharma launching autoimmune disorder drug
Sun Pharmaceutical Industries Ltd announced that a US court has ruled in its favour, immediately vacating a preliminary injunction that restricted the launch of LEQSELVI, a drug for treating autoimmune-related hair loss. This decision follows a patent infringement litigation with Incyte Corporation.
from Healthcare/Biotech-Industry-Economic Times...
Natco to sell rare spinal disease drug Risdiplam for ₹15,900
Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche sells Risdiplam on a discounted basis or one bottle free for each bottle purchased.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lyOqN4
via IFT...
ZIM Labs inks pact with Globalpharma Co to commercialise oral thin film products
ZIM Laboratories Ltd has entered into a licensing and supply agreement with UAE-based Globalpharma Co. to commercialize oral thin film (OTF) products in the Gulf Cooperation Council (GCC) region. The agreement involves a dossier license, product supply, and technology know-how license for ZIM's proprietary 'ThinOral' OTF technology platform.
from...
Trump signals major tariff on pharma imports, Indian drugmakers could face impact
Donald Trump announced a forthcoming "major" tariff on pharmaceutical imports, aiming to incentivize drug companies to relocate operations to the U.S. He also stated he warned Taiwan Semiconductor Manufacturing Company (TSMC) about potential taxes if they didn't establish U.S. plants. Trump criticized the Biden administration's $6.6 billion grant to...
As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population,...
India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance,...
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Rybelsus is a key driver, capturing 69% of the market. The introduction of Mounjaro and upcoming launch of Wegovy are expected to further accelerate growth, driven by rising lifestyle diseases and increased willingness...
PE firms bet on small-town hospitals for a growth shot
Non-metro locations, such as Lucknow , Vizag, Jaipur, Cochin, Siliguri, Guwahati, Bhubaneswar and Patna, private equity investors believe, hold great growth potential in healthcare, in lockstep with an increasing affordability quotient in tier- 2 or 3 towns, and a greater availability of qualified doctors and specialists.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma launches medication for Erosive Esophagitis
Sun Pharmaceutical Industries has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.
from...
Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform Eli Lilly's Mounjaro. Regulatory approval for Wegovy's cardiovascular benefits has been granted, pending final approval, allowing cardiologists to prescribe it.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pK6I3uf
via...
Govt plans capacity building activities for frontline workers of HPV vaccination
The Union Health Ministry plans to initiate capacity-building activities for frontline workers administering the HPV vaccine to girls aged 9-14 years to prevent cervical cancer. Following recommendations, the Ministry is finalizing strategies for this initiative. India accounts for a significant portion of global cervical cancer cases, with the vaccines...
Indians are quitting the safety net of health insurance; GST and high premiums are only part of the problem
Rising health insurance premiums and frequent claim rejections have led more Indians to drop their coverage. Despite the introduction of GST and government schemes, escalating costs leave many struggling to afford insurance, prompting calls for regulatory reforms to stabilize healthcare expenses.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vrU5ClS
via...
Kerala launches digital payment system, online services in govt hospitals
Kerala Health Minister Veena George announced the introduction of digital payment systems in 313 government hospitals to facilitate various service fee transactions. This system, part of the e-health initiative, employs POS devices from State Bank of India and Canara Bank, and includes capabilities such as the M-Health app and QR code-based ticket...
Now Pharma Inc looks for cure as Trump delivers dose of anxiety
US President Trump has announced that new tariffs on pharmaceuticals will be introduced soon, creating uncertainty for India's drug makers. Industry insiders are considering alternative markets to offset potential impacts, with companies preparing for any eventual developments.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T6McNyK
via...
T-Rx: Indian pharma majors breathe easy as US spares sector from reciprocal tariffs
Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.
from...
'Pharma's exemption from reciprocal tariffs underscores generic medicines' critical role globally'
The US Administration has exempted pharmaceuticals from reciprocal tariffs, highlighting the significance of affordable, life-saving generic medicines. The decision supports the vital trade partnership between India and the US, with Indian pharmaceutical companies supplying a substantial proportion of drugs to American residents and generating significant...
Big relief for India! Trump spares pharma from harsh tariffs
US President Trump has exempted India's pharmaceuticals from new reciprocal tariffs, benefiting the major export industry. This exemption highlights the significance of India's cost-effective generic medicines in US healthcare. The White House noted that removing trade barriers in other sectors could increase US exports by $5.3 billion annually.
from...
Fortis healthcare buys disputed Fortis trademark for Rs 200 crore
Fortis Healthcare has acquired the Fortis trademark from its former promoters, the Singh brothers, for Rs. 200 crore through a court-sanctioned auction. The trademark was involved in a litigation case with Japan's Daiichi Sankyo. Fortis Healthcare, now owned by IHH Healthcare, operates a network of 26 hospitals nationwide.
from Healthcare/Biotech-Industry-Economic...
Lupin acquires UK-based firm for 12.3 million pounds
Lupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to expand in the UK market with Renascience's products for infectious diseases, ear pain, and cardiovascular and renal treatment. This move supports Lupin's mission to provide accessible healthcare solutions.
from...
Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.
from Healthcare/Biotech-Industry-Economic...
360 ONE, Claypond Capital get CCI nod to acquire stakes in API Holdings
Fair trade regulator CCI has approved 360 ONE and Claypond Capital Partners' joint proposal to acquire stakes in API Holdings. This transaction involves purchasing compulsorily convertible preference shares from MEMG Family Office LLP, indicating oversight to prevent unfair business practices and ensure fair competition.
from Healthcare/Biotech-Industry-Economic...